4‐n‐butylresorcinol enhances proteolytic degradation of tyrosinase in B16F10 melanoma cells

Abstract Objective 4‐n‐butylresorcinol is a competitive inhibitor of tyrosinase and has been used as an antimelanogenic agent. However, its inhibition mechanism in intact cells is not fully understood. To elucidate the cellular mechanism, we compared in vitro and in vivo inhibitory effects of 4‐n‐butylresorcinol on tyrosinase activity. Methods B16F10 melanoma cells were cultured in media containing α ‐ MSH in the presence or absence of 4‐n‐butylresorcinol. Tyrosinase mRNA levels, protein levels and activity in B16F10 cells were compared by real‐time PCR , immunostaining combined with western blot and colorimetric analysis, respectively. Melanin concentration was measured by colorimetry both in the cells and in the media. Tyrosinase glycosylation and proteolytic degradation were analysed by immunoblotting after cells were treated with Endo H/ PNG ase F and E64/proteasome inhibitors, respectively. Results 4‐n‐butylresorcinol inhibited tyrosinase activity and melanin synthesis more effectively in intact cells than in cell lysates. Western blotting and real‐time RT ‐ PCR showed that 4‐n‐butylresorcinol reduced protein levels, but not mRNA levels, of tyrosinase in B16F10 cells. 4‐n‐butylresorcinol showed no effect on the processing of tyrosinase glycosylation or on trafficking to melanosomes. However, treatment of B16F10 cells with E64 or proteasome inhibitor abrogated the 4‐n‐butylresorcinol‐induced decrease of tyrosinase. Moreover, 4‐n‐butylresorcinol activated p38 MAPK , resulting in increased ubiquitination of tyrosinase. Conclusion 4‐n‐butylresorcinol inhibits melanogenesis by enhancing proteolytic degradation of tyrosinase as well as competitive binding to tyrosinase. These findings will help to develop new, effective and safe chemicals for the treatment of hyperpigmentation disorders.